Clinical trials
Relapsing Multiple Sclerosis clinical trials
Below are recruiting relapsing multiple sclerosis clinical trials, each written for real people, not researchers. We’re tracking 222 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04237675Recruiting
Study of MS relapses after surgery
This study looks at relapses (new or worsening MS symptoms) after surgery in people with multiple sclerosis (MS). It may help researchers understand what triggers relapse after surgery so better care can be planned.
Athens, AtticaAges 18–70 - NCT01703429Recruiting
Alternative care program for people with multiple sclerosis
This study looks at how a complementary or alternative care approach affects people living with multiple sclerosis. It may help to understand whether this type of program improves symptoms or quality of life over time.
Kenmore, WashingtonAges 18–100 - NCT04458688Recruiting
Ocrelizumab study for relapsing MS in African Americans and Caucasians
This study looks at how ocrelizumab works in people with relapsing-remitting multiple sclerosis (MS), and it specifically includes African American and Caucasian participants. Your neurologist may already be choosing ocrelizumab as the best standard treatment for you, and the study then follows you with medical visits and MRI scans.
Detroit, MichiganAges 18–60 - NCT05834855RecruitingPhase 3
Rituximab versus ocrelizumab for relapsing multiple sclerosis
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
AmsterdamAges 18 years+ - NCT05961644RecruitingPhase 2/Phase 3
Cladribine vs placebo for non-active progressive multiple sclerosis
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
Warsaw, Masovian VoivodeshipAges 30–65 - NCT04604041Recruiting
Study early warning signs in relapsing-remitting multiple sclerosis
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
SplitAges 18–65 - NCT05740722RecruitingPhase 2
Nicotinamide riboside for progressive multiple sclerosis
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
BergenAges 18–65 - NCT05204459Recruiting
MRI and eye-scan study for MS and related conditions
This trial uses brain MRI and eye imaging tests to study research markers in people with multiple sclerosis (MS) and related neurologic conditions. It may help researchers better understand these diseases and how they change over time.
Los Angeles, CaliforniaAges 18 years+ - NCT05832515RecruitingPhase 1
Stem cell transplant for multiple sclerosis with MS-prep chemotherapy
This early-phase study tests a stem cell transplant procedure for people with multiple sclerosis whose usual MS medicines have not worked or can’t be tolerated. The goal is to see if this approach can help control MS activity and progression, while checking for safety.
Saint PetersburgAges 18–65 - NCT03981003Recruiting
Blood tests to track brain and nerve changes in MS
This study measures blood markers (from a serum blood sample) to see how nerve and brain changes relate to MS disease activity and disability over time. It may help researchers better monitor MS, especially in people followed in the OFSEP program.
AmiensAges 15 years+ - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55 - NCT07840326RecruitingPhase 2
Study of SUN-627 for progressive multiple sclerosis
This study tests an experimental medicine called SUN-627 for people with progressive multiple sclerosis (MS) that is not currently flaring up. The goal is to see if it can slow down worsening disability without causing serious side effects.
Atlanta, GeorgiaAges 18–70 - NCT07826689RecruitingPhase 1/Phase 2
Oral pill for relapsing multiple sclerosis
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
Adelaide, South AustraliaAges 18–65 - NCT07827586Recruiting
Ocrelizumab injection for relapsing-remitting multiple sclerosis
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
LjubljanaAges 18 years+ - NCT07827716RecruitingPhase 2
Testing terfenadine for relapsing multiple sclerosis
This study tests whether terfenadine, an allergy medicine, is safe and helpful for people with relapsing-remitting multiple sclerosis (MS). It may reduce MS activity and improve outcomes.
Wuhan, HubeiAges 18–65 - NCT06461481Recruiting
Follow-up strategies for de-escalating multiple sclerosis treatment
This study tests different ways of monitoring people with relapsing-remitting MS who are reducing or stopping their medication. It aims to find the safest follow-up approach and may help guide future treatment decisions for those with stable disease.
DüsseldorfAges 18 years+ - NCT07804264Recruiting
Short sprint workouts for people with multiple sclerosis
This study tests whether brief, high-intensity interval training (short bursts of exercise) can help people with multiple sclerosis improve their fitness and daily function. It may be a good option if you have mild disability and can walk without major help.
Ponferrada, LeónAges 18–65 - NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT07736482Recruiting
How fatigue and disability affect obstacle stepping in MS
This study looks at how fatigue and disability affect your ability to step over an obstacle while walking—whether you are doing just that task or also doing a second task (like talking). It may help understand how MS affects everyday movement.
Afyonkarahisar, MerkezAges 18–65 - NCT07706114Enrolling by invitation
Walking with FES: a daily life study for MS
This trial tests whether daily use of Functional Electrical Stimulation (FES) can improve real-world walking and daily activities for people with multiple sclerosis. FES uses small electrical pulses to help weak leg muscles move.
San Francisco, CaliforniaAges 22–75 - NCT06663111Recruiting
Rituximab and Ocrelizumab levels in Multiple Sclerosis
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Bergen, VestlandAges 18–60 - NCT07648277Recruiting
Spine Position, Movement, and Balance in Multiple Sclerosis
This study examines how multiple sclerosis affects your spine alignment, flexibility, and balance. Understanding these changes may help develop better physical therapies and support for people living with MS.
Ankara, ÇubukAges 18–65
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Relapsing Multiple Sclerosis trials by city
Studies with a site in or near these metro areas.
Relapsing Multiple Sclerosis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for relapsing multiple sclerosis?
- Yes. Clin2 currently lists 222 recruiting relapsing multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsing multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsing multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Fatigue in Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.